This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

This study has been completed.
Sponsor:
Information provided by:
Universita di Verona
ClinicalTrials.gov Identifier:
NCT00477789
First received: May 23, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
May 23, 2007
May 23, 2007
Not Provided
Not Provided
diastolic function uric acid levels BNP [ Time Frame: three months ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients
Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients
In patients with chronic heart failure (CHF)due to dilated cardiomyopathy diastolic dysfunction occurs frequently and is related to a poor outcome. We have previously shown that parameters of diastolic function significantly correlate with uric acid levels, a marker of impaired oxidative metabolism. We aimed to determine whether inhibition of xanthine oxidase with allopurinol might affect diastolic function in patients with CHF.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Chronic Heart Failure
Drug: allopurinol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • chronic heart failure;
  • left ventricular systolic dysfunction (ejection fraction <45%)
  • stable clinical conditions in the previous three months
  • optimal medical therapy for CHF
  • normal sinus rhythm
  • written informed consent
  • age >18 years

Exclusion Criteria:

  • renal failure (s-creatinine >2.5 mg/dl)
  • already on allopurinol
  • malignancies
  • chronic inflammatory diseases
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT00477789
802
No
Not Provided
Not Provided
Not Provided
Universita di Verona
Not Provided
Principal Investigator: Mariantonietta Cicoira, MD, PhD Division of Cardiology, University of Verona, Italy
Universita di Verona
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP